BioCentury
ARTICLE | Company News

Idera, Vivelix deal

December 2, 2016 9:08 PM UTC

Idera granted Vivelix exclusive, worldwide rights to develop and commercialize IMO-9200 to treat non-malignant gastrointestinal disorders. Idera will receive $15 million up front and is eligible for up to $65 million in development and regulatory milestones, up to $75 million in sales milestones and royalties ranging from mid-single digits to low-double digits. ...